Patient Access Network Foundation uses the following criteria to
determine eligibility for assistance:
1. You have to be insured and your insurance has to cover the
medication for which you are seeking assistance.
2. The medication you take must fight the disease directly.
3. You have to be a US resident.
4. Your income must fall below 400% of the Federal Poverty
Level.
Click
here
for the Federal Poverty Guidelines
applications for new and renewal patients are accepted and
grants are immediately allocated.
Oncology Cytoprotection refers to treatments that are designed to support and protect cancer patients during specific treatment regimens that may include radiation therapy and/or chemotherapy. Without access to such treatments, patients may be unable to complete treatment for lung, breast, or head and neck cancer. Because toxicities associated with chemotherapy and radiotherapy can adversely affect short- and long-term patient quality of life, can limit the dose and duration of treatment, and may be life-threatening, specific agents designed to ameliorate or eliminate certain chemotherapy and radiotherapy toxicities are available for patients.
Cytoprotection treats toxicities and other complications associated with chemotherapy and radiation therapy. These treatments can minimize disruption of patient care as well as support more rigorous therapy options. Treatment options for cytoprotection are often IV administered in the physician office or hospital outpatient setting.
The primary payer for this patient population is Medicare, followed by private payers; however, both can lead to access issues for many patients. Medicare lacks a cap on coinsurance, and private coverage can vary dramatically, leaving many patients with extremely high co-payments and out-of-pocket maximums. As a result, low to moderate income beneficiaries are often unable to afford the prescribed therapies. The Patient Access Network Foundation may be able to provide these patients assistance with their cost sharing requirements.
